Ketotifen Unit Dose Stulln (Ketotifen)

Ketotifen blocks histamine H1 receptors on mast cells in the conjunctiva and stabilizes those cells, preventing the release of histamine and other inflammatory mediators. This dual action reduces the allergic response and alleviates ocular symptoms.

The dosing regimen for Ketotifen Unit Dose Stulln is determined by the prescribing clinician based on the severity of the allergic condition and patient response. The product is supplied as a unit‑dose drop, and the prescriber specifies the number of drops and frequency.

Safety data for ketotifen ophthalmic use in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any unknown risks and consider alternative therapies if appropriate. Pregnant or nursing patients should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ketotifen combines antihistamine activity with mast‑cell stabilization, offering both immediate symptom relief and longer‑term control. Some other ocular antihistamines provide only H1‑receptor blockade, which may require more frequent dosing for comparable effect.

Store the unit‑dose ophthalmic solution at room temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from light and moisture, and discard any unit dose that appears discolored or compromised.

The product is supplied as a single‑use dropper. The patient instills one drop into the affected eye(s) as directed by the prescriber, typically several times a day. Hands should be washed before use, and the dropper tip must not touch the eye or any surface.

While rare, serious adverse events can include severe allergic reactions such as angioedema, corneal ulceration, or persistent eye pain that may threaten vision. Any of these symptoms require immediate medical evaluation and discontinuation of the product.

Patients with a known hypersensitivity to ketotifen or any component of the formulation should avoid use. Those with active ocular infections should treat the infection first, and individuals with uncontrolled glaucoma should use the product only under close ophthalmic supervision.